Roche's Cindy Perettie named EVP of Kite
Gilead Sciences (Nasdaq: GILD) has announced that Cindy Perettie will join the firm as executive vice president of its subsidiary company Kite, overseeing the cell therapy business.
Ms Perettie will also become a member of Gilead’s senior leadership team, effective May 30, bringing with her extensive experience in oncology, which is now a major focus for the Californian biotech company.
"The cell therapy business continues to play an important role in Gilead’s ambition to become a top oncology company"Most recently, Ms Perettie was head of Roche’s (ROG: SIX) Molecular Lab Solutions, where she oversaw the polymerase chain reaction and sequencing business. Prior to that, she was chief executive at Roche-owned Foundation Medicine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze